(Reuters) - Medtronic Plc has agreed to stop manufacturing and distributing its SynchroMed implantable drug pump, U.S. regulators said on Monday, a step toward resolving allegations that the company violated quality standards with the device which delivers pain medication to cancer patients and others.
Medtronic failed to correct problems that could lead to a patient receiving too much or too little medication, the U.S. Department of Justice said in a statement on Monday. The DOJ said the company will change its manufacturing process and will not be required to recall existing devices.
Help employers find you! Check out all the jobs and post your resume.
